Insmed Inc (STU:IM8N)
€ 67 0.5 (0.75%) Market Cap: 11.95 Bil Enterprise Value: 11.50 Bil PE Ratio: 0 PB Ratio: 25.75 GF Score: 63/100

Insmed Inc Phase 3 ARISE Topline Results Transcript

Sep 05, 2023 / 12:30PM GMT
Release Date Price: €21.4 (+2.88%)
Operator

Good morning. My name is Rob and I will be your conference operator today. At this time, I would like to welcome everyone to the Insmed Phase III ARISE Top Line Results Conference Call. (Operator Instructions). Bryan Dunn, Executive Director, Investor Relations, you may begin your conference.

Bryan Dunn

Thank you, Rob. Good day, everyone and welcome to today's conference call to discuss the top line results of the Phase III ARISE study of ARIKAYCE in patients with newly diagnosed or recurrent MAC lung disease who have not started antibiotics.

I am joined today by Will Lewis, Chair and Chief Executive Officer; Martina Flammer, Chief Medical Officer; and Dr. Charles Daley, who is Chief of the Division of Mycobacterial and Respiratory Infections at National Jewish Health, a key opinion leader in the treatment of patients with NTM MAC lung infection and the primary investigator in the ARISE study.

The call will begin with opening remarks from Will before turning it over to Martina to walk us through the results. Following Martina, we will ask Dr. Daley

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot